Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 9121843, 6 pages
http://dx.doi.org/10.1155/2016/9121843
Research Article

Nao-Xue-Shu Oral Liquid Protects and Improves Secondary Brain Insults of Hypertensive Cerebral Hemorrhage

1Department of Radiology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China
2Department of Respiratory Medicine, Pudong Hospital of Traditional Chinese Medicine, Shanghai 201209, China
3Shanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, China
4Department of Neurology, Shanghai Seventh Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China
5Department of Neurology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China

Received 13 December 2015; Revised 19 February 2016; Accepted 10 March 2016

Academic Editor: Giuseppe Esposito

Copyright © 2016 Hongning Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aim. To determine one traditional Chinese medicine (TCM) Nao-Xue-Shu oral liquid which protects and improves secondary brain insults (SBI) in hypertensive cerebral hemorrhage (HCH). Methods. 158 patients with HCH were divided into routine clinical medicine plus Nao-Xue-Shu oral liquid () as treatment group, and routine clinical medicine () only served as the control group. The incidence of SBI and the classification of a favorable prognosis and a bad prognosis using the Glasgow outcome scale (GOS) were assessed to evaluate the clinical effects. The changes of IL-6 and TNF-α levels were determined to study the mechanism of the effects for the TCM. Results. The incidence of SBI at the end of week 2 was 8.97% in the treatment group and 23.75% in the control group, and the difference was significant (). The incidence of a favorable prognosis was 48.72% in the treatment group and 32.72% in the control group, and the difference was significant () at the end of week 2. These findings indicate clear differences for IL-6 and TNF-α at the end of week 1 and week 2 compared with before treatment for the treatment group and a marked difference at the end of week 2 between the two groups. It also shows a significant difference between the end of week 2 and before treatment for IL-6 and TNF-α for the control group, although the difference was much smaller than the treatment group. Conclusion. Nao-Xue-Shu oral liquid could protect against the occurrence of SBI and improve HCH and SBI patients. It may also decrease the damage and the mass effects of the hematoma by reducing IL-6 and TNF-α to obtain the effects, and thus it is a potentially suitable drug for HCH and SBI.